Alceus Bio

Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours.

Its platform uses generative AI and synthetic biology to design therapeutic proteins that patient-derived immune cells are programmed to express and deliver in situ, targeting intracellular disease drivers inaccessible to conventional therapies.

The company's multimodal CAR-T architecture is designed to engage tumours through multiple coordinated mechanisms, addressing the resistance and immunosuppressive challenges that limit existing cell therapies in solid cancers.